Is there still a role for tremelimumab in the treatment of cancer?

被引：5

作者：

Ascierto, Paolo A. ^{[1
]}

机构：

[1] Ist Tumori Fdn Pascale, Unit Melanoma Canc Immunotherapy & Innovat Therap, Naples, Italy

来源：

TRANSLATIONAL CANCER RESEARCH | 2013年 / 2卷 / 01期

关键词：

D O I：

10.3978/j.issn.2218-676X.2013.02.02

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

It was surprising to first learn, at the 2008 ASCO annual meeting, that the phase III trial of tremelimumab for the treatment of advanced melanoma did not have a positive result with regard to its primary endpoint. After very promising data in phase II studies, the difference in overall survival (OS) between the tremelimumab and standard of care control (temozolomide or dacarbazine) arms was not statistically significant (11.8 versus 10.7 months). Despite this, at that point in time, an OS of 11.8 months for advanced melanoma patients seemed exceptional, given the historical median OS of 6-8 months for these patients (1). © 2011 - 2016 Translational Cancer Research.

引用

页码：48 / 50

页数：3

共 9 条

[1]

Ipilimumab: Unleashing the Power of the Immune System Through CTLA-4 Blockade [J].

Boasberg, Peter ;

Hamid, Omid ;

O'Day, Steven .

SEMINARS IN ONCOLOGY, 2010, 37 (05) :440-449

[2]

Phase I/II Trial of Tremelimumab in Patients With Metastatic Melanoma [J].

Camacho, Luis H. ;

Antonia, Scott ;

Sosman, Jeffrey ;

Kirkwood, John M. ;

Gajewski, Thomas F. ;

Redman, Bruce ;

Pavlov, Dmitri ;

Bulanhagui, Cecile ;

Bozon, Viviana A. ;

Gomez-Navarro, Jesus ;

Ribas, Antoni .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (07) :1075-1081

[3]

Therapeutic vaccines in solid tumours: Can they be harmful? [J].

Eggermonf, Alexander M. M. .

EUROPEAN JOURNAL OF CANCER, 2009, 45 (12) :2087-2090

[4]

Hersh E, 2012, PIGM CELL MELANOMA R, V25, P863

[5]

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma [J].

Hodi, F. Stephen ;

O'Day, Steven J. ;

McDermott, David F. ;

Weber, Robert W. ;

Sosman, Jeffrey A. ;

Haanen, John B. ;

Gonzalez, Rene ;

Robert, Caroline ;

Schadendorf, Dirk ;

Hassel, Jessica C. ;

Akerley, Wallace ;

van den Eertwegh, Alfons J. M. ;

Lutzky, Jose ;

Lorigan, Paul ;

Vaubel, Julia M. ;

Linette, Gerald P. ;

Hogg, David ;

Ottensmeier, Christian H. ;

Lebbe, Celeste ;

Peschel, Christian ;

Quirt, Ian ;

Clark, Joseph I. ;

Wolchok, Jedd D. ;

Weber, Jeffrey S. ;

Tian, Jason ;

Yellin, Michael J. ;

Nichol, Geoffrey M. ;

Hoos, Axel ;

Urba, Walter J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (08) :711-723

[6]

Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials [J].

Korn, Edward L. ;

Liu, Ping-Yu ;

Lee, Sandra J. ;

Chapman, Judith-Anne W. ;

Niedzwiecki, Donna ;

Suman, Vera J. ;

Moon, James ;

Sondak, Vernon K. ;

Atkins, Michael B. ;

Eisenhauer, Elizabeth A. ;

Parulekar, Wendy ;

Markovic, Svetomir N. ;

Saxman, Scott ;

Kirkwood, John M. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (04) :527-534

[7]

Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma [J].

Ribas, Antoni ;

Kefford, Richard ;

Marshall, Margaret A. ;

Punt, Cornelis J. A. ;

Haanen, John B. ;

Marmol, Maribel ;

Garbe, Claus ;

Gogas, Helen ;

Schachter, Jacob ;

Linette, Gerald ;

Lorigan, Paul ;

Kendra, Kari L. ;

Maio, Michele ;

Trefzer, Uwe ;

Smylie, Michael ;

McArthur, Grant A. ;

Dreno, Brigitte ;

Nathan, Paul D. ;

Mackiewicz, Jacek ;

Kirkwood, John M. ;

Gomez-Navarro, Jesus ;

Huang, Bo ;

Pavlov, Dmitri ;

Hauschild, Axel .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (05) :616-622

[8]

Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma [J].

Robert, Caroline ;

Thomas, Luc ;

Bondarenko, Igor ;

O'Day, Steven ;

Weber, Jeffrey ;

Garbe, Claus ;

Lebbe, Celeste ;

Baurain, Jean-Francois ;

Testori, Alessandro ;

Grob, Jean-Jacques ;

Davidson, Neville ;

Richards, Jon ;

Maio, Michele ;

Hauschild, Axel ;

Miller, Wilson H., Jr. ;

Gascon, Pere ;

Lotem, Michal ;

Harmankaya, Kaan ;

Ibrahim, Ramy ;

Francis, Stephen ;

Chen, Tai-Tsang ;

Humphrey, Rachel ;

Hoos, Axel ;

Wolchok, Jedd D. .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (26) :2517-2526

[9]

Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria [J].

Wolchok, Jedd D. ;

Hoos, Axel ;

O'Day, Steven ;

Weber, Jeffrey S. ;

Hamid, Omid ;

Lebbe, Celeste ;

Maio, Michele ;

Binder, Michael ;

Bohnsack, Oliver ;

Nichol, Geoffrey ;

Humphrey, Rachel ;

Hodi, F. Stephen .

CLINICAL CANCER RESEARCH, 2009, 15 (23) :7412-7420

← 1 →